Using the questions presented in the Celgene Case, answer the questions in a report format. Change the acquired company to Juno Therapeutics, Inc. (Juno). While you can access the annual report at the Celgene website (www.celgene.com), I found the 10-K filing with the SEC to be more user friendly. To access it, go to www.sec.gov. Click on "Company Filings." Use "Celgene Corp" for the search. When you get to Celgene's page, use "10-K" in the "Filing Type" box. That brings all the 10-K's that have been filed to the top of the list. I would suggest using "Interactive Data" for your research.

Thank you!

On August 27, 2015, Celgene Corporation acquired all of the outstanding stock of Receptos, Inc., in exchange for $7.6 billion in cash. Referring to Celgene's 2015 financial statements and its July 14, 2015, press release announcing the acquisition, answer the following questions regarding the Receptos acquisition. 1. Why did Celgene acquire Receptos? 2. What accounting method was used, and for what amount, to record the acquisition? 3. What amount did Celgene include in pre-combination service compensation in the total consideration transferred? What support is provided for this treatment in the Accounting Standards Codification (see ASC 805-30-30, paragraphs 9-13)? 4. What allocations did Celgene make to the assets acquired and liabilities assumed in the acquisition? Provide a calculation showing how Celgene determined the amount allocated to goodwill. 5. Describe the nature of the in-process research and development product rights acquired by Celgene in its acquisition of Receptos. 6. How will Celgene account for the in-process research and development product rights acquired in the Receptos combination? On August 27, 2015, Celgene Corporation acquired all of the outstanding stock of Receptos, Inc., in exchange for $7.6 billion in cash. Referring to Celgene's 2015 financial statements and its July 14, 2015, press release announcing the acquisition, answer the following questions regarding the Receptos acquisition. 1. Why did Celgene acquire Receptos? 2. What accounting method was used, and for what amount, to record the acquisition? 3. What amount did Celgene include in pre-combination service compensation in the total consideration transferred? What support is provided for this treatment in the Accounting Standards Codification (see ASC 805-30-30, paragraphs 9-13)? 4. What allocations did Celgene make to the assets acquired and liabilities assumed in the acquisition? Provide a calculation showing how Celgene determined the amount allocated to goodwill. 5. Describe the nature of the in-process research and development product rights acquired by Celgene in its acquisition of Receptos. 6. How will Celgene account for the in-process research and development product rights acquired in the Receptos combination